MA29688B1 - Formulation d'un inhibiteur de l'agregation plaquettaire thienopyridine - Google Patents

Formulation d'un inhibiteur de l'agregation plaquettaire thienopyridine

Info

Publication number
MA29688B1
MA29688B1 MA30568A MA30568A MA29688B1 MA 29688 B1 MA29688 B1 MA 29688B1 MA 30568 A MA30568 A MA 30568A MA 30568 A MA30568 A MA 30568A MA 29688 B1 MA29688 B1 MA 29688B1
Authority
MA
Morocco
Prior art keywords
formulation
plaquetry
thienopyridine
aggregation inhibitor
aggregation
Prior art date
Application number
MA30568A
Other languages
English (en)
Inventor
David Brian Dziennik
Tamara Beth Edelman
Peter Lloyd Oren
Robert Louis Ternik
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37198935&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29688(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA29688B1 publication Critical patent/MA29688B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

L'invention concerne une formulation d'un composé de formule (I), un procédé de préparation correspondant et des méthodes pour utiliser ladite formulation.
MA30568A 2005-06-10 2008-01-09 Formulation d'un inhibiteur de l'agregation plaquettaire thienopyridine MA29688B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68918305P 2005-06-10 2005-06-10

Publications (1)

Publication Number Publication Date
MA29688B1 true MA29688B1 (fr) 2008-08-01

Family

ID=37198935

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30568A MA29688B1 (fr) 2005-06-10 2008-01-09 Formulation d'un inhibiteur de l'agregation plaquettaire thienopyridine

Country Status (35)

Country Link
US (1) US20080176893A1 (fr)
EP (1) EP1896019B1 (fr)
JP (1) JP2008543755A (fr)
KR (2) KR20100076050A (fr)
CN (1) CN101193633B (fr)
AR (1) AR054283A1 (fr)
AT (1) ATE441413T1 (fr)
AU (1) AU2006258102B2 (fr)
BR (1) BRPI0611350B8 (fr)
CA (1) CA2611668C (fr)
CY (1) CY1109502T1 (fr)
DE (1) DE602006008942D1 (fr)
DK (1) DK1896019T3 (fr)
DO (1) DOP2006000126A (fr)
EA (1) EA011693B1 (fr)
EC (1) ECSP077984A (fr)
ES (1) ES2330373T3 (fr)
HK (1) HK1116422A1 (fr)
HR (1) HRP20090516T1 (fr)
IL (1) IL187830A0 (fr)
MA (1) MA29688B1 (fr)
MX (1) MX2007015431A (fr)
MY (1) MY151038A (fr)
NO (1) NO20076317L (fr)
NZ (1) NZ564003A (fr)
PE (1) PE20070320A1 (fr)
PL (1) PL1896019T3 (fr)
PT (1) PT1896019E (fr)
RS (1) RS51194B (fr)
SI (1) SI1896019T1 (fr)
TN (1) TNSN07466A1 (fr)
TW (1) TWI318571B (fr)
UA (1) UA91051C2 (fr)
WO (1) WO2006135605A2 (fr)
ZA (1) ZA200710697B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0719398A2 (pt) * 2006-12-07 2015-03-31 Daiichi Sankyo Company Ltd E Ube Ind Ltd Composição farmacêutica.
BRPI0719393B8 (pt) * 2006-12-07 2021-05-25 Daiichi Sankyo Co Ltd composição farmacêutica
US20100179184A1 (en) * 2006-12-07 2010-07-15 Matthew John Moon Article of manufacture for prasugrel
BRPI0719394A2 (pt) * 2006-12-07 2015-03-31 Daiichi Sankyo Company Ltd E Ube Ind Ltd Preparação medicinal sólida
JPWO2008069262A1 (ja) * 2006-12-07 2010-03-25 第一三共株式会社 安定性が改善されたフィルムコーティング製剤
WO2008072533A1 (fr) * 2006-12-07 2008-06-19 Daiichi Sankyo Company, Limited Procédé de production d'une préparation solide
NZ579993A (en) * 2007-03-02 2012-06-29 Daiichi Sankyo Co Ltd Process for production of prasugrel hydrochloride having high purity
ES2855700T3 (es) 2007-04-27 2021-09-24 Cydex Pharmaceuticals Inc Formulaciones que contienen clopidogrel y sulfoalquil éter-ciclodextrina y métodos de uso
GB2450117A (en) * 2007-06-13 2008-12-17 Reckitt Benckiser Healthcare A water- and oxygen-occlusive blister tablet pack
DE112009000268T5 (de) 2008-02-06 2011-06-01 Helm Ag Prasugrel-Salze mit verbesserten Eigenschaften
EP2107061A1 (fr) * 2008-04-02 2009-10-07 Krka Tovarna Zdravil, D.D., Novo Mesto Procédé de préparation de clopidogrel enrichi optiquement
ES2353853T3 (es) 2008-04-25 2011-03-07 Sandoz Ag SAL HIDROGENOSULFATO DE 2-ACETOXI-5-("ALFA"-CICLOPROPILCARBONIL-2-FLUORBENCIL)-4,5,6,7-TETRAHIDROTIENO[3,2-c]PIRIDINA Y SU PREPARACIÓN.
EA024980B1 (ru) * 2009-02-17 2016-11-30 КРКА, д.д., НОВО МЕСТО Лекарственные формы, содержащие основание прасугреля или его фармацевтически приемлемые соли присоединения кислоты, и способы их приготовления
CN104606681B (zh) 2009-05-13 2018-08-21 锡德克斯药物公司 包含普拉格雷和环糊精衍生物的药物组合物及其制备和使用方法
DE102009036646A1 (de) 2009-08-07 2011-02-10 Ratiopharm Gmbh Prasugrel in nicht-kristalliner Form und pharmazeutische Zusammensetzung davon
JP2013032289A (ja) * 2009-10-28 2013-02-14 Daiichi Sankyo Co Ltd ワックス安定製剤
WO2011052499A1 (fr) * 2009-10-28 2011-05-05 第一三共株式会社 Composition pharmaceutique présentant une stabilité au stockage améliorée
WO2011092720A2 (fr) * 2010-02-01 2011-08-04 Msn Laboratories Limited Composition pharmaceutique de prasugrel et ses sels pharmaceutiquement acceptables
TR201005900A1 (tr) 2010-07-19 2012-02-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Geliştirilmiş stabiliteye sahip prasugrel granülleri.
TR201007926A1 (tr) 2010-07-19 2012-02-21 Sanovel İlaç San.Ve Ti̇c.A.Ş. Prasugrel tablet formülasyonları.
EP2409685A3 (fr) 2010-07-19 2012-02-01 Sanovel Ilac Sanayi ve Ticaret A.S. Formulations de prasugrel à désintégration orale
TR201006802A1 (tr) * 2010-08-17 2012-03-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Prasugrelin oral yolla dağılan formülasyonları.
CZ2011872A3 (cs) 2011-12-22 2013-07-03 Zentiva, K.S. Farmaceutická formulace prasugrelu hydrobromidu
US8603537B2 (en) 2012-04-02 2013-12-10 Egis Pharmaceuticals Plc Prasugrel containing quickly released stable oral pharmaceutical compositions
WO2014060560A1 (fr) 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Formulations orales solides de prasugrel
WO2014060554A1 (fr) 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Formulations de prasugrel
CN102993210A (zh) * 2012-12-19 2013-03-27 苏春华 一种吡啶并噻吩的新化合物
EP2979693A1 (fr) 2014-08-01 2016-02-03 Zaklady Farmaceutyczne Polpharma SA Composition pharmaceutique comprenant du prasugrel ou un sel pharmaceutiquement acceptable de celui-ci et son procédé de préparation
WO2016122421A1 (fr) 2015-01-29 2016-08-04 Pharmactive Ilaç Sanayi Ve Ticaret A.Ş. Compositions pharmaceutiques stables contenant une base de prasugrel
EP3158993A1 (fr) 2015-10-22 2017-04-26 Zaklady Farmaceutyczne Polpharma SA Procédé pour préparer un comprimé contenant du prasugrel ou des sels pharmaceutiquement acceptables de celui-ci
CN107304216A (zh) * 2016-04-20 2017-10-31 陕西合成药业股份有限公司 噻吩吡啶类衍生物及其制备方法和用途
HU231079B1 (hu) 2016-06-23 2020-06-29 Richter Gedeon Nyrt. Eljárás nagytisztaságú Prasugrel előállítására bromopentil szennyezés eltávolításával
GR1009230B (el) 2016-10-12 2018-02-22 Φαρματεν Αβεε Φαρμακευτικο σκευασμα που περιλαμβανει βεσυλικη πρασουγρελη

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101150B (fi) * 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
KR20130118395A (ko) * 2000-07-06 2013-10-29 다이이찌 산쿄 가부시키가이샤 히드로피리딘 유도체 산부가염
JP4001199B2 (ja) * 2000-07-06 2007-10-31 第一三共株式会社 ヒドロピリジン誘導体酸付加塩
EP1243524A3 (fr) * 2001-03-16 2004-04-07 Pfizer Products Inc. Trousse pharmaceutique pour médicaments sensibles a l'oxygène
JP4394873B2 (ja) * 2001-12-19 2010-01-06 武田薬品工業株式会社 酸素に不安定な化合物を含有する固形組成物およびその安定化方法
SI21302A (sl) * 2002-10-11 2004-04-30 LEK farmacevtska dru�ba d.d. Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
US20050020554A1 (en) * 2003-06-06 2005-01-27 Ahmed Salah U. Stability of hormone formulations
ATE381322T1 (de) * 2003-08-05 2008-01-15 Zentiva As Verfahren zur stabilisierung von atorvastatin

Also Published As

Publication number Publication date
CN101193633A (zh) 2008-06-04
ECSP077984A (es) 2008-01-23
ATE441413T1 (de) 2009-09-15
PE20070320A1 (es) 2007-05-12
DOP2006000126A (es) 2006-12-15
PT1896019E (pt) 2009-11-19
ZA200710697B (en) 2009-08-26
DE602006008942D1 (en) 2009-10-15
EP1896019B1 (fr) 2009-09-02
US20080176893A1 (en) 2008-07-24
EA200702670A1 (ru) 2008-04-28
AR054283A1 (es) 2007-06-13
IL187830A0 (en) 2008-04-13
MY151038A (en) 2014-03-31
TW200718420A (en) 2007-05-16
CN101193633B (zh) 2011-12-14
WO2006135605A2 (fr) 2006-12-21
JP2008543755A (ja) 2008-12-04
AU2006258102A1 (en) 2006-12-21
TWI318571B (en) 2009-12-21
MX2007015431A (es) 2008-02-21
BRPI0611350A2 (pt) 2010-12-07
NZ564003A (en) 2011-07-29
TNSN07466A1 (en) 2009-03-17
AU2006258102B2 (en) 2011-09-15
KR20100076050A (ko) 2010-07-05
NO20076317L (no) 2008-02-29
BRPI0611350B1 (pt) 2020-09-15
PL1896019T3 (pl) 2010-01-29
CA2611668C (fr) 2013-10-15
CA2611668A1 (fr) 2006-12-21
EA011693B1 (ru) 2009-04-28
DK1896019T3 (da) 2009-10-26
HRP20090516T1 (en) 2009-10-31
SI1896019T1 (sl) 2010-01-29
BRPI0611350B8 (pt) 2021-05-25
UA91051C2 (ru) 2010-06-25
EP1896019A2 (fr) 2008-03-12
KR20080008413A (ko) 2008-01-23
HK1116422A1 (en) 2008-12-24
WO2006135605A3 (fr) 2007-04-12
ES2330373T3 (es) 2009-12-09
RS51194B (sr) 2010-10-31
CY1109502T1 (el) 2014-08-13

Similar Documents

Publication Publication Date Title
MA29688B1 (fr) Formulation d'un inhibiteur de l'agregation plaquettaire thienopyridine
MA35452B1 (fr) 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
EA200870321A1 (ru) Способ получения 4-оксохинолинового соединения
MX2009007075A (es) Metodos de uso para analogos de ciclopamina.
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
MA34644B1 (fr) Dérivés de pyrazole aminopyrimidine en tant que modulateurs du lrrk2
MXPA05009969A (es) Metodo para aislar la forma cristalina i de la 5-azacitidina.
MA29539B1 (fr) Procedes de production de derives phenoliques 4-biphenylylazetidin -2-one
TN2010000171A1 (fr) Derives de thienopyrimidine et pyrazolopyrimidine et leur utilisation comme inhibiteurs de la kinase mtor te de la kinase k13
EA200970156A1 (ru) Пиридизиноновые производные
TN2010000052A1 (fr) Derives de pyrazole et leur utilisation comme inhibiteurs de raf
MX2009003834A (es) Derivados de pirrolidina como inhibidores de iap.
MA35434B1 (fr) Amino-quinazolines en tant qu'inhibiteurs de kinase
BRPI0518203A2 (pt) mÉtodos para preparaÇço de compostos indazol
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
EA201000883A1 (ru) Производные индолинона и способ их получения
TW200637539A (en) CTGF inhibitors
MX2009005649A (es) Tratamiento para mieloma multiple.
MA30757B1 (fr) Inhibiteurs de l'akt (proteine kinase b)
MX2010008226A (es) Derivados de difluorobifenilamida para el tratamiento de hipertension ocular.